Vanda Pharmaceuticals Inc (VM4.SG)
| Previous close | 4.6400 |
| Open | 4.5600 |
| Bid | 4.8400 x 250000 |
| Ask | 4.9200 x 250000 |
| Day's range | 4.5600 - 4.9000 |
| 52-week range | 3.0400 - 6.2500 |
| Volume | |
| Avg. volume | 154 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Reuters
Butler Hall Capital urges Vanda to engage in sales discussions
Hedge fund manager Butler Hall Capital said on Friday it is urging Vanda Pharmaceuticals to form an independent special committee to engage with Future Pak over its takeover offer and run a full sales process. On April 17, Vanda rejected a takeover proposal from Future Pak and adopted a shareholder rights plan to reduce the likelihood of a hostile takeover. Vanda had said Future Pak, a privately held contract manufacturer and packager of pharmaceutical products, had made an offer of $7.25 to $7.75 per share in cash, which significantly undervalued the company and was not in the shareholders' best interest.
ZacksVanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up
Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.
ZacksInvestors Heavily Search Vanda Pharmaceuticals Inc. (VNDA): Here is What You Need to Know
Zacks.com users have recently been watching Vanda (VNDA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
